Corporate news announcement processed and transmitted by Hugin AS.
The issuer is solely responsible for the content of this 
announcement. 
----------------------------------------------------------------------
--------------    




-         Trial results show 45% overall reduction in 28-day all
cause mortality with talactoferrin versus placebo
-         Talactoferrin again shown to be very well tolerated
-         Conference call and webcast scheduled for Wednesday,
December 2  at 9 AM ET/3 PM CET

Martinsried/Munich (Germany), Princeton, NJ and Houston, TX, December
1, 2009 - Agennix AG  (Frankfurt Stock Exchange: AGX) today  reported
results   from    the   talactoferrin    randomized,    double-blind,
placebo-controlled  Phase  2  trial  in  severe  sepsis.   The  trial
evaluated talactoferrin  versus placebo  in 190  adult patients  with
severe sepsis  enrolled  at  25  leading  centers  across  the  U.S.
Patients in both arms  also received standard  of care treatment  for
severe sepsis in  an intensive  care unit (ICU)  setting.  The  trial
achieved its  primary endpoint  of a  reduction in  28-day  all-cause
mortality.  The trial showed a 45% reduction in the 28-day  all-cause
mortality from 26.6% in the placebo arm to 14.6% in the talactoferrin
arm (two-tailed p-value  = 0.04,  odds ratio  by logistic  regression
analysis = 0.47).

"We  are  very   excited  to   see  such   compelling  results   with
talactoferrin in severe  sepsis, a  life-threatening and  notoriously
hard-to-treat  disease,"  said  Rajesh  Malik,  M.D.,  Chief  Medical
Officer.   "There  are  currently  very  limited  treatment   options
available, with only one drug  in the U.S. approved specifically  for
severe sepsis, a  disease that  results in hundreds  of thousands  of
deaths each year in the U.S. and Europe alone.  Given the strength of
these clinical  trial  results,  we  plan  to  talk  with  regulatory
authorities, as well as key  opinion leaders and potential  partners,
about advancing talactoferrin for this indication."
Patients were  stratified by  clinical site  and by  the presence  or
absence of cardiovascular dysfunction.  Cardiovascular dysfunction is
a major prognostic  factor for  severe sepsis.  A  similar number  of
patients had cardiovascular dysfunction in the two treatment  groups.
Sixty-four percent  (64%)  of  patients (n=121)   in  the  trial  had
cardiovascular  dysfunction  and  36%  (n=69)  did  not.   For  those
patients with cardiovascular dysfunction, 28-day all cause  mortality
was 28.6% for the placebo arm  and 22.4% for the talactoferrin  arm.
For patients who did not have cardiovascular dysfunction, 28-day  all
cause mortality was 22.6% in the placebo arm compared to 2.6% in  the
talactoferrin  arm.   When  the  trial  results  were  adjusted   for
cardiovascular dysfunction, the two-tailed p-value was 0.06, and  the
odds ratio was 0.49.

The above analyses were all conducted on an intent-to-treat (ITT), as
treated basis,  meaning that  patients were  evaluated based  on  the
treatment they actually received (talactoferrin or placebo).  An  ITT
as treated analysis is a method to address patient assignment  errors
in a way that mitigates the potential impact on the data analysis  of
a trial.   In  this study,  the  quality control  process  identified
errors in drug labeling and  randomization during the conduct of  the
trial that affected the drug  assignment for some patients.  That  is
why this analysis was used, following feedback from the U.S. Food and
Drug Administration (FDA).  To determine if the assignment error  had
an impact on the outcome of the trial, as recommended by the FDA, the
Company conducted a sensitivity analysis evaluating 28-day all  cause
mortality by  excluding  22  patients who  mistakenly  received  both
talactoferrin and placebo.  This analysis indicated that there was no
apparent effect of the  patient assignment errors  on the outcome  of
the trial.  The  sensitivity analysis  showed that  28-day all  cause
mortality in the  placebo arm  was 25.9%  compared to  15.1% for  the
talactoferrin arm.

Talactoferrin was shown to be very  well tolerated in the study  with
no major  differences in  adverse events  between the  two  treatment
arms.

The study  included  96 patients  in  the talactoferrin  arm  and  94
patients in  the  placebo  arm.   In  addition,  four  patients  were
randomized but did not receive study drug due to withdrawal prior  to
receiving the first dose.  All  patients were centrally screened  for
eligibility prior to randomization.  The  arms were well balanced  in
terms of baseline characteristics.

The Phase  2 trial  was primarily  funded by  a grant  from the  U.S.
National Institutes of Health.

The Company plans to present data from the trial at an upcoming major
medical meeting.


Conference call scheduled
The Company has scheduled a conference call to which participants may
listen via live webcast, accessible  through the Agennix Web site  at
www.agennix.com or via telephone. A  replay will be available on  the
Web site following the live event. The call, which will be  conducted
in English, will  be held  on Wednesday,  December 2,  2009 at  15:00
CET/9:00 AM ET. The dial-in numbers for the call are as follows:

Participants in Europe:  0049 69 667775756
                                         0044 20 3003 2666
Participants in the U.S.: 1-646 843 4608

Please dial in 10 minutes before the beginning of the call.

About severe sepsis
Sepsis is  a condition  involving known  or suspected  infection  and
generalized inflammation.  The body's normal response to an infection
is to set off  a limited chain reaction  to fight the infection.   In
severe sepsis, this systemic response escalates into an  overreaction
by the body that  leads to dysfunction of  one or more organs.   Each
year, approximately 750,000  people in North  America develop  severe
sepsis, and a similar number of people are affected in Europe.  Those
figures are expected to  rise due to the  aging population and  other
factors.   Approximately  30%  of  people  with  severe  sepsis   are
estimated to die annually  from this condition in  the U.S., and  the
U.S. Centers for Disease Control and Prevention indicates that sepsis
is one of the top ten leading  causes of death in the U.S.   Patients
suffering from  severe  sepsis  must be  hospitalized,  often  in  an
intensive care  unit,  and the  medical  costs to  treat  sepsis  are
estimated to be over $16 billion annually in the U.S. alone.

About talactoferrin
Talactoferrin is an oral novel targeted dendritic cell recruiter  and
activator  being  studied  mainly   for  the  treatment  of   cancer.
Talactoferrin  has   demonstrated   anti-cancer   activity   in   two
randomized,  double-blind,  placebo-controlled  Phase  2  studies  in
non-small cell lung cancer (NSCLC).  NSCLC is one of the most  common
types of  cancer worldwide  and  the most  frequent cause  of  cancer
death. As a result of the promising results from Phase 2 studies, two
Phase 3 studies  with talactoferrin  in NSCLC  have been  initiated.
Talactoferrin has also  shown activity  in renal  cell carcinoma,  as
well as severe sepsis.  Talactoferrin has been shown to be very  well
tolerated in  these  patient populations.   The  Company also  has  a
topical formulation of talactoferrin for wound healing.


About Agennix
Agennix AG is a publicly traded biopharmaceutical company focused  on
developing novel anti-cancer therapies. The Company was formed by the
combination of GPC Biotech AG and Agennix Incorporated. The Company's
most advanced program is talactoferrin, an oral targeted therapy that
is in Phase 3  clinical trials in non-small  cell lung cancer.  Other
clinical development  programs include  RGB-286638, a  multi-targeted
kinase inhibitor in Phase 1 testing; the oral platinum-based compound
satraplatin; and  a  topical  gel form  of  talactoferrin  for  wound
healing. Agennix is  a transatlantic  company with  sites in  Munich,
Germany; Princeton,  New Jersey  and Houston,  Texas. For  additional
information, please visit the Agennix Web site at www.agennix.com.

This press release contains forward-looking statements, which express
the current beliefs and expectations of the management of Agennix AG.
Such statements are based on current expectations and are subject  to
risks and uncertainties, many of  which are beyond our control,  that
could cause  future results,  performance or  achievements to  differ
significantly from the results, performance or achievements expressed
or implied  by  such  forward-looking statements.  There  can  be  no
guarantee  that  the  Company  will  move  talactoferrin  forward  in
development for severe sepsis in a timely manner, if at all, or  that
talactoferrin will ultimately  be approved for  sale in any  country.
Actual results  could  differ materially  depending  on a  number  of
factors, and we caution investors not to place undue reliance on  the
forward-looking  statements   contained   in  this   press   release.
Forward-looking statements speak only  as of the  date on which  they
are made  and  Agennix  undertakes  no  obligation  to  update  these
forward-looking statements, even if new information becomes available
in the future.


For further information, please contact:

Agennix AG
Investor Relations & Corporate Communications
Phone: +49 (0)89 8565 2693
ir@agennix.com

In the U.S.: Laurie Doyle
Director, Investor Relations & Corporate Communications
Phone: +1 609 524 5884
laurie.doyle@agennix.com

Additional media contacts for Europe:
MC Services AG
Phone: +49 (0) 89 210 228 0

Raimund Gabriel
raimund.gabriel@mc-services.eu

Hilda Juhasz
hilda.juhasz@mc-services.eu

Additional investor contact for Europe:
Trout International LLC
Lauren (Rigg) Williams, Vice President
Phone: +44 207 936 9325
lwilliams@troutgroup.com


 
--- End of Message ---

Agennix AG
Fraunhoferstr. 20 Martinsried Germany

ISIN: 
DE000A1A6XX4; 
Listed: Regulierter Markt in Frankfurter Wertpapierbörse, Prime 
Standard in Frankfurter Wertpapierbörse;



Copyright © Hugin AS 2009. All rights reserved.